trientine has been researched along with Left Ventricular Hypertrophy in 3 studies
Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.
TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group.
2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trientine is a highly selective copper II chelator." | 3.30 | Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy. ( Akhtar, M; Ashkir, Z; Baroja, O; Bedson, E; Clayton, D; Cooper, RM; Dodd, S; Duran, B; Farrant, J; Garratt, C; Harrington, C; Mahmod, M; Miller, CA; Naish, JH; Neubauer, S; Prasad, SK; Raman, B; Reid, A; Schmitt, M; Singh, A; Spowart, C; Valkovič, L; Vaughan, C, 2023) |
| "Trientine treatment decreased LVM(bsa) by 5." | 2.74 | A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study. ( Baker, JR; Brunton, DH; Cooper, GJ; Cowan, BR; Dissanayake, AM; Doughty, RN; Frampton, CM; Gamble, GD; Occleshaw, CJ; Phillips, AR; Poppitt, SD; Young, AA, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Farrant, J | 1 |
| Dodd, S | 1 |
| Vaughan, C | 1 |
| Reid, A | 1 |
| Schmitt, M | 1 |
| Garratt, C | 1 |
| Akhtar, M | 1 |
| Mahmod, M | 1 |
| Neubauer, S | 1 |
| Cooper, RM | 1 |
| Prasad, SK | 1 |
| Singh, A | 1 |
| Valkovič, L | 1 |
| Raman, B | 1 |
| Ashkir, Z | 1 |
| Clayton, D | 1 |
| Baroja, O | 1 |
| Duran, B | 1 |
| Spowart, C | 1 |
| Bedson, E | 1 |
| Naish, JH | 1 |
| Harrington, C | 1 |
| Miller, CA | 1 |
| Zhang, L | 1 |
| Ward, ML | 1 |
| Phillips, AR | 2 |
| Zhang, S | 1 |
| Kennedy, J | 1 |
| Barry, B | 1 |
| Cannell, MB | 1 |
| Cooper, GJ | 2 |
| Young, AA | 1 |
| Gamble, GD | 1 |
| Occleshaw, CJ | 1 |
| Dissanayake, AM | 1 |
| Cowan, BR | 1 |
| Brunton, DH | 1 |
| Baker, JR | 1 |
| Frampton, CM | 1 |
| Poppitt, SD | 1 |
| Doughty, RN | 1 |
2 trials available for trientine and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy.
Topics: Cardiomyopathy, Hypertrophic; Copper; Fibrosis; Heart; Humans; Hypertrophy, Left Ventricular; Trient | 2023 |
A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study.
Topics: Adult; Aged; Blood Pressure; Body Surface Area; Chelating Agents; Creatinine; Diabetes Mellitus, Typ | 2009 |
1 other study available for trientine and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Protection of the heart by treatment with a divalent-copper-selective chelator reveals a novel mechanism underlying cardiomyopathy in diabetic rats.
Topics: Animals; Calcium; Cardiotonic Agents; Chelating Agents; Copper; Diabetes Mellitus, Experimental; Dia | 2013 |